Companies Cryptocurrencies
Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Exchange: Nasdaq Global Select
IPO Date: 28/07/2000
CEO: Mr. Amit Munshi
Biotechnology Healthcare 🔗
  • ARNA
  • 99.99
  • 6165323264
    market cap
  • 0
If you bought

shares of Arena Pharmaceuticals Inc (ARNA) on
You would have made
Old Price $12 Current Price $12

Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. The company is headquartered in San Diego, California and currently employs 194 full-time employees. The firm is focused on developing small molecule drugs across a range of therapeutic areas. The firm has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The firm’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The firm’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The firm’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Address: 6154 Nancy Ridge Dr San Diego CALIFORNIA 92121

Stay updated.